Loading...
Loading...

Go to the content (press return)

Recommendations to choose the primary endpoint in cardiovascular clinical trials

Author
Gómez Melis, Guadalupe; Gomez, M.; Dafni, U.
Type of activity
Report
Date
2013
Code
Report DR 2013/08
Repository
http://hdl.handle.net/2117/21995 Open in new window
Abstract
Background – A composite endpoint is often used as the primary endpoint to assess the efficacy of a new treatment in randomized clinical trials (RCT). In cardiovascular trials, the often rare event of the relevant primary endpoint (individual or composite), such as cardiovascular death (CV death), Myocardial Infarction (MI), or both, is combined with a more common secondary endpoint, such as target lesion revascularization, with the aim to increase the statistical power of the study. Methods ...
Citation
Gomez, G.; Gomez, M.; Dafni, U. "Recommendations to choose the primary endpoint in cardiovascular clinical trials". 2013.
Keywords
Asymptotic Relative Efficiency, Cardiovascular, Composite outcome, Logrank test, Randomized Clinical Trial
Group of research
GRBIO - Biostatistics and Bioinformatics Research Group

Participants